No results for ‘’
Astrazeneca Pharma India Ltd
₹8396
(0.67%)
Wed, 17 Jun 2026, 04:03 pm
Health Technology
Pharmaceuticals: Major
24.5KAstrazeneca Pharma India PB Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 29.61 | 30.61 | 26.62 | 16.73 | 41.18 | 60.81 | 262.27 | 0 | 0 | 0 | 550.79 | 117.59 | 89.09 | 91.75 | 82.80 | 80.66 | 103.71 | 81.76 | 82.35 | 185.90 |
| Price to book ratio | 10.03 | 10.52 | 10.27 | 10.63 | 16.42 | 17.36 | 27.40 | 16.39 | 16.08 | 15.21 | 18.53 | 10.55 | 9.38 | 16.61 | 16.41 | 19.61 | 14.55 | 15.72 | 20.80 | 30.82 |
| Price to sales ratio | 5.66 | 5.53 | 5.38 | 3.49 | 5.98 | 6.57 | 9.51 | 4.19 | 5.83 | 4.89 | 5.13 | 4.33 | 4.06 | 6.86 | 7.19 | 9.31 | 7.93 | 8.09 | 10.27 | 12.54 |
| Price to cash flow ratio | 41.19 | 25.14 | 37.56 | 13.51 | 65.23 | 44.69 | 120.68 | 0 | 972.64 | 0 | 46.80 | 53.74 | 138.20 | 75.69 | 60.18 | 65.96 | 57.09 | 99.68 | 221.83 | 221.49 |
| Enterprise value | 1208Cr | 1383Cr | 1525Cr | 1154Cr | 2306Cr | 3044Cr | 5135Cr | 1616Cr | 2671Cr | 2267Cr | 2815Cr | 2236Cr | 2190Cr | 4822Cr | 5738Cr | 7185Cr | 5949Cr | 7625Cr | 12800Cr | 21015Cr |
| Enterprise value to EBITDA ratio | 19.65 | 19.16 | 16.91 | 10.25 | 25.70 | 36.69 | 114.81 | 0 | 0 | 0 | 168.15 | 59.71 | 44.76 | 67.12 | 47.01 | 54.18 | 67.31 | 45.59 | 68.56 | 81.55 |
| Debt to equity ratio | 0 | 0 | 0 | 0.54 | 0.01 | 0.05 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 | 0.05 |
| Return on equity % | 38.66 | 36.25 | 40.83 | 53.61 | 44.21 | 31.65 | 10.71 | -61.95 | -0.38 | -12.93 | 3.43 | 10.58 | 12.12 | 19.88 | 21.71 | 24.94 | 14.97 | 20.79 | 27.95 | 17.31 |
Astrazeneca Pharma India Ltd Price to Book Ratio
The Astrazeneca Pharma India Ltd Price to Book Ratio is a key financial metric used by investors to evaluate Astrazeneca Pharma India Ltd's valuation, profitability, and overall financial performance. Tracking the Astrazeneca Pharma India Ltd Price to Book Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Astrazeneca Pharma India Ltd (NSE: ASTRAZEN, BSE: 506820) is currently trading at ₹8396, with a market capitalization of ₹20958.5Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Astrazeneca Pharma India Ltd Price to Book Ratio is essential for fundamental analysis.
Astrazeneca Pharma India Ltd Price to Book Ratio Current Value
The current Astrazeneca Pharma India Ltd Price to Book Ratio stands at 30.82.
The latest Astrazeneca Pharma India Ltd Price to Book Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Astrazeneca Pharma India Ltd Price to Book Ratio Historical Trend
The Astrazeneca Pharma India Ltd Price to Book Ratio has shown the following historical trend:
- 2024: 30.82
- 2023: 20.80
- 2022: 15.72
- 2021: 14.55
- 2020: 19.61
The recent rise in Astrazeneca Pharma India Ltd Price to Book Ratio suggests strengthening valuation trends and improving market sentiment.
What Astrazeneca Pharma India Ltd Price to Book Ratio Indicates for Investors
The Astrazeneca Pharma India Ltd Price to Book Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/B ratio shows how the market values company assets relative to book value.
Astrazeneca Pharma India Ltd Price to Book Ratio Analysis Summary
The Astrazeneca Pharma India Ltd Price to Book Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Astrazeneca Pharma India Ltd Price to Book Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Astrazeneca Pharma India Ltd Price to Book Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.